Sydney Lupkin

The U.K.

will increase the prices its health service pays for new medicines by 25 percent and will reduce rebates paid by drug makers.

That's according to the Office of the United States Trade Representative.

In exchange, U.K.

drugs, drug ingredients, and medical technology will be exempt from U.S.

tariffs for at least three years.

Sydney Lupkin, NPR News.

People buying Wagovi directly from Novo Nordisk will now be able to get it for around $350 a month.

Until the end of next March, the company will offer the first two months doses at around $200 a month.

That's down from about $500 a month.

And patients can get the same discount from Costco, GoodRx, Weight Watchers, and Rowe, according to the company.

The lower price is only available to patients not using their health insurance.

Novo Nordisk's announcement follows the Trump administration's deals with Novo Nordisk and Eli Lilly earlier this month.

The deals included lower direct-to-consumer costs of the company's blockbuster obesity drugs.

But even the discounted prices will still be too high for many patients.

Sydney Lepkin, NPR News.

The number of adults taking GLP-1 drugs, which include Ozempic, Wagovi, Zephound, and Manjaro, is going up.

It went from 6% a year and a half ago to 12% now.

People are taking the drugs for chronic conditions like type 2 diabetes and heart disease, as well as for weight loss.

Here's Ashley Kurtzinger, a pollster at KFF.